Gilead Sciences/$GILD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Gilead Sciences

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Ticker

$GILD
Sector
Primary listing

Employees

17,600

Gilead Sciences Metrics

BasicAdvanced
$140B
22.46
$5.01
0.35
$3.12
2.81%

What the Analysts think about Gilead Sciences

Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.

Bulls say / Bears say

The European Commission's approval of lenacapavir for twice-yearly HIV PrEP is expected to drive up to $4 billion in annual sales by 2029, significantly bolstering Gilead's long-term HIV prevention franchise. (Reuters)
Gilead's Q2 2025 HIV product sales grew 7% to $5.1 billion, driven by strong demand and higher prices, enabling the company to raise its full-year revenue and earnings guidance. (Reuters)
The strategic partnership and license agreement with Kymera Therapeutics, valued at up to $750 million, expands Gilead's oncology pipeline with novel CDK2 molecular glue degraders, reinforcing its long-term growth in cancer therapeutics. (Reuters)
Cell therapy revenues fell 7% to $485 million in Q2 2025 as competitive pressure in the CAR-T space intensified, undermining Gilead's cell therapy growth prospects. (Reuters)
Liver disease portfolio sales declined 4% to $795 million in Q2 2025, driven by lower hepatitis C sales amid generic competition and pricing pressures, weighing on Gilead's liver disease franchise. (Reuters)
Despite EU approval of lenacapavir as a twice-yearly HIV PrEP option, its high annual list price of over $28,000 and protracted, country-specific reimbursement negotiations could delay or limit uptake in major European markets. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.

Gilead Sciences Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Gilead Sciences Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GILD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Sept15
Gilead Sciences
Dividend·Ex-dividend
Sept29
Gilead Sciences
Dividend·Payment
$0.79Per share
FAQs